GLP-1
Liraglutide
SaveA once-daily GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). Demonstrated cardiovascular benefit in the LEADER trial.
Quick verdict
A well-proven GLP-1 RA with dual FDA approvals and cardiovascular outcome data. Weight loss (~8% in SCALE trials) is less than semaglutide but clinically meaningful.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
The LEADER trial showed a 13% reduction in major cardiovascular events. The SCALE obesity trials demonstrated approximately 8% mean weight loss versus placebo at 3.0 mg/day. Extensive post-marketing safety data is available.
Benefits
- Dual FDA approval for diabetes and obesity
- Cardiovascular risk reduction (LEADER)
- Extensive long-term safety data
Dosage notes
Diabetes: titrate to 1.8 mg/day. Obesity: titrate to 3.0 mg/day over 4–5 weeks.
Side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
Who should be cautious
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. GI side effects are common, especially during dose escalation.
What this page cannot tell you
Daily injection is less convenient than weekly alternatives. Weight loss magnitude is surpassed by semaglutide and tirzepatide.
Leaderboard scores
- Weight loss72
Write a review
Sign in to write a review.